FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2297097601> ?p ?o ?g. }

• W2297097601 endingPage "144" @default.
• W2297097601 startingPage "137" @default.
• W2297097601 abstract "Osteonecrosis of the femoral head (ONFH) is a devastating disease with complete collapse of the femoral head often reported in greater than 70% of patients within 3 to 4 years of diagnosis. Early intervention prior to collapse may improve the chance of success of joint preserving procedures.The purpose of this study was to evaluate whether core decompression with mesenchymal stem cells combined with bisphosphonate therapy can improve the clinical outcomes and reduce the risk of hip replacement when compared to treatment with bisphosphonate therapy alone.Between 2006 and 2014, 84 consecutive patients who were diagnosed with ONFH were identified from our institution's registry. Of these 84 patients, 49 patients (62 hips), fit inclusion/exclusion criteria. Twenty-nine patients (40 hips) were treated with bisphosphonate therapy only. Twenty patients (20 hips) were treated with bisphosphonates, core decompression, and mesenchymal stem cells. Functional outcomes were assessed using the Modified Harris Hip Score (MHHS), the visual analog score (VAS), and evaluation of support system. Clinical failure was defined as deterioration of the MHHS/VAS scores and support system used severe enough to require THR. Radiologic outcome measures included the XR and MR imaging staging of the hip. Survival analysis was performed with total hip replacement as the end point failure. Collapse was defined as progression from Ficat stage I or II to stage III and from Steinberg I, II, III to IV, V, VI.Failure requiring THR occurred in 21/40 (52.5%) of bisphosphonates (BP)-treated hips at a mean follow-up of 25.3 ± 11.5 months and 5/22 (22.73%) of BP + CD + MSC-treated hips at a mean follow-up of 22.7 ± 19.5 months. The median (Q1, Q3) time to collapse was 24.9 (7.4, 33.0) months in BP-treated hips and 27.3 (27.3) months in BP + CD + MSC-treated hips. There was no evidence of a difference in functional outcomes between the two treatment groups. After adjusting for baseline Ficat stage, age, and sex, an unreplaced hip treated with BP + CD + MSC had 0.42 (95% CI 0.11, 1.57) times the risk of being replaced in the next moment compared to an unreplaced hip treated with bisphosphonates only (P = 0.196).Our results demonstrate that treatment with BP alone or BP + CD + MSC can postpone the need for total hip arthroplasty (THA) in the first 24 months in patients with ONFH compared to previously reported data, but there is no statistically significant difference between the two treatment groups. Combination therapy of BP + CD + MSC may be more effective in delaying the progression of collapse in early stage ONFH. Future prospective studies are warranted to determine the efficacy of these treatment strategies in the long term." @default.
• W2297097601 created "2016-06-24" @default.
• W2297097601 creator A5005145185 @default.
• W2297097601 creator A5009120422 @default.
• W2297097601 creator A5019201057 @default.
• W2297097601 creator A5021115355 @default.
• W2297097601 creator A5025278481 @default.
• W2297097601 creator A5044704313 @default.
• W2297097601 creator A5069751385 @default.
• W2297097601 creator A5082730902 @default.
• W2297097601 date "2016-03-17" @default.
• W2297097601 modified "2023-10-17" @default.
• W2297097601 title "The Efficacy of Bisphosphonates with Core Decompression and Mesenchymal Stem Cells Compared with Bisphosphonates Alone in the Treatment of Osteonecrosis of the Hip: a Retrospective Study" @default.
• W2297097601 cites W171827598 @default.
• W2297097601 cites W1898460111 @default.
• W2297097601 cites W1965432241 @default.
• W2297097601 cites W1967894844 @default.
• W2297097601 cites W1987650869 @default.
• W2297097601 cites W2000786890 @default.
• W2297097601 cites W2003745782 @default.
• W2297097601 cites W2004501693 @default.
• W2297097601 cites W2017319337 @default.
• W2297097601 cites W2019097079 @default.
• W2297097601 cites W2026622347 @default.
• W2297097601 cites W2033180641 @default.
• W2297097601 cites W2034027092 @default.
• W2297097601 cites W2043303130 @default.
• W2297097601 cites W2047719697 @default.
• W2297097601 cites W2057734869 @default.
• W2297097601 cites W2090978105 @default.
• W2297097601 cites W2103190706 @default.
• W2297097601 cites W2146253518 @default.
• W2297097601 cites W2146758211 @default.
• W2297097601 cites W2157431909 @default.
• W2297097601 cites W2159649211 @default.
• W2297097601 cites W2167929640 @default.
• W2297097601 cites W2169928924 @default.
• W2297097601 cites W2181932044 @default.
• W2297097601 cites W23346594 @default.
• W2297097601 cites W80856442 @default.
• W2297097601 doi "https://doi.org/10.1007/s11420-016-9487-7" @default.
• W2297097601 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4916091" @default.
• W2297097601 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27385942" @default.
• W2297097601 hasPublicationYear "2016" @default.
• W2297097601 type Work @default.
• W2297097601 sameAs 2297097601 @default.
• W2297097601 citedByCount "18" @default.
• W2297097601 countsByYear W22970976012017 @default.
• W2297097601 countsByYear W22970976012018 @default.
• W2297097601 countsByYear W22970976012019 @default.
• W2297097601 countsByYear W22970976012020 @default.
• W2297097601 countsByYear W22970976012021 @default.
• W2297097601 countsByYear W22970976012022 @default.
• W2297097601 countsByYear W22970976012023 @default.
• W2297097601 crossrefType "journal-article" @default.
• W2297097601 hasAuthorship W2297097601A5005145185 @default.
• W2297097601 hasAuthorship W2297097601A5009120422 @default.
• W2297097601 hasAuthorship W2297097601A5019201057 @default.
• W2297097601 hasAuthorship W2297097601A5021115355 @default.
• W2297097601 hasAuthorship W2297097601A5025278481 @default.
• W2297097601 hasAuthorship W2297097601A5044704313 @default.
• W2297097601 hasAuthorship W2297097601A5069751385 @default.
• W2297097601 hasAuthorship W2297097601A5082730902 @default.
• W2297097601 hasBestOaLocation W22970976011 @default.
• W2297097601 hasConcept C126322002 @default.
• W2297097601 hasConcept C141071460 @default.
• W2297097601 hasConcept C14184104 @default.
• W2297097601 hasConcept C146357865 @default.
• W2297097601 hasConcept C151730666 @default.
• W2297097601 hasConcept C198451711 @default.
• W2297097601 hasConcept C2776211809 @default.
• W2297097601 hasConcept C2776541429 @default.
• W2297097601 hasConcept C2777251235 @default.
• W2297097601 hasConcept C2779100257 @default.
• W2297097601 hasConcept C3020453552 @default.
• W2297097601 hasConcept C68312169 @default.
• W2297097601 hasConcept C71924100 @default.
• W2297097601 hasConcept C86803240 @default.
• W2297097601 hasConceptScore W2297097601C126322002 @default.
• W2297097601 hasConceptScore W2297097601C141071460 @default.
• W2297097601 hasConceptScore W2297097601C14184104 @default.
• W2297097601 hasConceptScore W2297097601C146357865 @default.
• W2297097601 hasConceptScore W2297097601C151730666 @default.
• W2297097601 hasConceptScore W2297097601C198451711 @default.
• W2297097601 hasConceptScore W2297097601C2776211809 @default.
• W2297097601 hasConceptScore W2297097601C2776541429 @default.
• W2297097601 hasConceptScore W2297097601C2777251235 @default.
• W2297097601 hasConceptScore W2297097601C2779100257 @default.
• W2297097601 hasConceptScore W2297097601C3020453552 @default.
• W2297097601 hasConceptScore W2297097601C68312169 @default.
• W2297097601 hasConceptScore W2297097601C71924100 @default.
• W2297097601 hasConceptScore W2297097601C86803240 @default.
• W2297097601 hasIssue "2" @default.
• W2297097601 hasLocation W22970976011 @default.
• W2297097601 hasLocation W22970976012 @default.
• W2297097601 hasLocation W22970976013 @default.
• W2297097601 hasLocation W22970976014 @default.
• W2297097601 hasOpenAccess W2297097601 @default.

• next